PureTech Health (LSE:PRTC) wholly owns Gallop Oncology, which has presented phase 1b results showing LYT-200 plus a hypomethylating agent produced a 45.5% overall response rate in 11 evaluable patients with relapsed or refractory high-risk myelodysplastic syndromes. The company plans a randomised phase 2 trial but will start it only after securing external capital.

What was announced

PureTech Health plc (LSE:PRTC) said on 26 October 2026 that Gallop Oncology, a PureTech Founded Entity that PureTech founded and wholly owns, presented phase 1b results for LYT-200 at the ESMO Congress 2026 in Madrid. The data were presented in an oral session by Guenther Koehne, Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at Baptist Health Herbert Wertheim Cancer Institute.

LYT-200 is a first-in-class, fully human monoclonal antibody that targets galectin-9, which the company describes as an oncogenic driver and immunosuppressor. PureTech also describes the approach as mutation-agnostic.

The phase 1b trial (NCT05829226) was run at nine US sites and enrolled 101 heavily pretreated patients. It included a dose-escalation stage of LYT-200 as monotherapy, followed by LYT-200 combined with a hypomethylating agent (HMA), either azacitidine or decitabine, in relapsed or refractory high-risk myelodysplastic syndromes (R/R HR-MDS), and LYT-200 combined with venetoclax and an HMA in relapsed or refractory acute myeloid leukaemia (AML).

The numbers

In R/R HR-MDS, patients treated with LYT-200 at 12 mg/kg plus an HMA had a complete response plus partial response rate of 36.4% and an overall response rate of 45.5%. These figures relate to 11 efficacy-evaluable patients, from an intention-to-treat cohort of 12. All of the evaluable patients had previously received HMA therapy, with a median of three prior lines of treatment (range one to five), and all had high-risk cytogenetics.

Two patients achieved complete responses with no detectable measurable residual disease (MRD-negative) and went on to stem cell transplantation. Responses were seen across a range of mutations, including BCOR, DNMT3A, SF3B1, TET2, PTPN11, KRAS and RUNX1-RUNX1T1.

The release does not report confidence intervals, survival data, follow-up duration or efficacy results for the AML cohort, and it makes no claim of statistical significance. Given the small number of evaluable patients and the absence of a control arm, the response rates are early signals rather than evidence of comparative benefit.

On safety, across all 101 patients and all cohorts and dose levels, there were no dose-limiting toxicities, no infusion-related reactions and no LYT-200 dose reductions. PureTech said there were no LYT-200-related serious adverse events, discontinuations or deaths, and no overlapping or additive toxicities when LYT-200 was combined with an HMA or with venetoclax and an HMA.

Dr Koehne said the results provide an "encouraging foundation for evaluating LYT-200 in a larger, randomized study."

Regulatory status and next steps

LYT-200 has received US Food and Drug Administration Fast Track designation for R/R HR-MDS in combination with an HMA, and for AML. Gallop has also held what the company describes as a successful End-of-Phase 1 meeting with the FDA.

The next planned study is STRIDE-MDS, a randomised, double-blind, placebo-controlled phase 2 trial in about 125 patients with R/R HR-MDS. Patients would be randomised 2:2:1 to LYT-200 at 12 mg/kg plus an HMA, LYT-200 at 7.5 mg/kg plus an HMA, or placebo plus an HMA. The primary assessment will be complete and partial response rates, to support dose selection.

What to watch next

The key point for investors is funding. Gallop plans to begin STRIDE-MDS only after securing external capital, and the release gives no detail on the amount needed, potential partners or a timetable. Any financing or partnering announcement for Gallop would therefore determine when the phase 2 study can start.

Further disclosure on the AML cohort, including efficacy figures not given in this release, and longer follow-up on the duration of responses in HR-MDS would also help clarify the profile of the drug.